Literature DB >> 25956042

A randomized, phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate- or high-risk diffuse large B-cell lymphoma.

John D Hainsworth1,2, Edward R Arrowsmith1,2, Michael McCleod1,3, Eric D Hsi4, Oday Hamid5, Peipei Shi5, Boris K Lin5, Luis E Fayad6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25956042     DOI： 10.3109/10428194.2015.1045898

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  8 in total

Review 1.  Treatment resistance in diffuse large B-cell lymphoma.

Authors:  Michael Y He; Robert Kridel
Journal:  Leukemia       Date:  2021-05-20       Impact factor: 11.528

2.  Functional role of regulatory T cells in B cell lymphoma and related mechanisms.

Authors:  Wei Wu; Jun Wan; Ruixiang Xia; Zhenqi Huang; Jing Ni; Mingzhen Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

Review 3.  Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma.

Authors:  Brian G Till
Journal:  Curr Treat Options Oncol       Date:  2018-07-21

4.  Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?

Authors:  Arushi Khurana; Raphael Mwangi; Grzegorz S Nowakowski; Thomas M Habermann; Stephen M Ansell; Betsy R LaPlant; Brian K Link; James R Cerhan; Matthew J Maurer; Thomas E Witzig
Journal:  J Clin Oncol       Date:  2021-02-02       Impact factor: 44.544

5.  Why R-CHOP + X is not enough: lessons learned and next steps in the mission to improve frontline therapy for diffuse large B-cell lymphoma.

Authors:  Hua-Jay J Cherng; Jason Westin
Journal:  Leuk Lymphoma       Date:  2021-01-06

Review 6.  New agents and regimens for diffuse large B cell lymphoma.

Authors:  Liang Wang; Lin-Rong Li; Ken H Young
Journal:  J Hematol Oncol       Date:  2020-12-14       Impact factor: 17.388

7.  A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high/high-intermediate risk diffuse large B-cell lymphoma.

Authors:  N M Reddy; J P Greer; D S Morgan; H Chen; S I Park; K L Richards
Journal:  Leukemia       Date:  2016-09-22       Impact factor: 11.528

Review 8.  DLBCL 1L-What to Expect beyond R-CHOP?

Authors:  Maike Stegemann; Sophy Denker; Clemens A Schmitt
Journal:  Cancers (Basel)       Date:  2022-03-11       Impact factor: 6.639
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.